MATCH SIGNED

Project "MATCH" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

The advances in medical sciences and biopharmaceutical development during the last decennia have been overwhelming. While the scientific and clinical insight in numerous diseases have significantly increased, the curative treatment to most diseases is still not in reach. The most common diseases such as cancer and chronic diseases are still challenging scientists. Therefore, during our ERC Advanced project the main goal was to develop a vaccine to cure cancer using targeted immunotherapy. We used dendritic cells (DCs) as potentiator to improve anti-tumor T cell activity. However, we discovered that many tumors display a high content of sialic acids which actively suppress DCs function and induce tolerance to tumor associated antigens. This unexpected serendipity finding that sialylation of tumor associated antigens induced tolerance to the body’s immune response opens a window of opportunity to use sialylation (modification with sialic acid) to induce tolerance in allergies, such as house dust mite allergy (HDM). In the ERC PoC project (MATCH) I will couple HDM major allergens to specific sialic acid using a linker molecule to induce immune tolerance towards effector T cells in inflammation processes during HDM allergy. The results will lead to validation of the technology developed during the ERC Advanced project and PoC that sialylation induces tolerance when used with HDM allergens. When PoC is reached, the MATCH technology will represent a new allergen immunotherapy in a vaccine technology for HDM allergy with shorter treatment protocols, better efficacy and reduced side effects can be developed. The future potential of this technology may be extended to other allergies and/or autoimmune diseases.